Examine detailed studies published in top medical journals that outline how physicians, radiologists, and researchers are using Cortechs.ai’s groundbreaking AI image analysis software to elevate diagnosis and treatment of neurodegenerative diseases and cancer.
Deep learning reconstruction allows 60% sequence scan-time reduction while maintaining high volumetric quantification
accuracy, consistent clinical classification, and what radiologists perceive as superior image quality compared with standard of care. This trial supports the reliability, efficiency, and utility of deep learning-based enhancement for quantitative imaging. Shorter scan times may heighten the use of volumetric quantitative MR imaging in routine clinical settings.
The automated volumetric assessment tool had moderate sensitivity (63.3%) and high specificity (100%) in differentiating patients with mild-to-moderate AD from control subjects. Visual inspection showed sensitivity of 63.3% and specificity of 92.0%. The diagnostic performance was not significantly different between the two methods (p =0.536–0.906). Intraobserver reliability for visual inspection was 0.858 and 0.902 for the two reviewers, and interobserver reliability was 0.692–0.780. (2016).
Magnetic resonance spectroscopy (MRS) has long showed promise for detection of regional chemical changes associated with neurodegeneration, infl ammation, or gliosis, and so it has been a technique of interest for detecting such changes in AD. It provides information about relative concentrations of key chemicals, such as N acetylaspartate, creatinine, and myoinositol, and there is strong evidence that the regional concentration of these chemicals varies with the neurodegeneration seen in AD. (2013).
This study examined whether measures of hippocampus, amygdala, and temporal horn volume predict clinical decline over the following 6-month period in patients with mild cognitive impairment (MCI). Fully automated volume measurements were performed in 269 MCI patients. Baseline volumes of the hippocampus, amygdala, and temporal horn were evaluated as predictors of change in Mini-mental State Examination and Clinical Dementia Rating Sum of Boxes over a 6-month interval. Fully automated measurements of baseline hippocampus and amygdala volumes correlated with baseline delayed recall scores. (2009).
Based on the evidence reviewed, the idea that brain volume changes and, to a lesser extent, spinal cord atrophy are helpful predictors of the evolution of MS before initiation of therapy is undisputed, so these measures could be valid treatment-decision tools. The evidence reviewed also supports the idea that brain volume measures have value in monitoring the effects of MS drugs as part of the no evidence of disease activity outcome measure or minimal evidence of disease activity outcome measure. However, several potential sources of substantial error remain, including, but not limited to, differential effects of drugs on brain volume measures, confounding physiological and technical factors and the performance and value of volumetric tools. To make implementation of volume measurements in clinical practice feasible, these potential sources of error need to be accounted for and appropriately managed, and further research is needed to ensure the accuracy and reliability of the measurements. (2020).
Thalamic atrophy and whole brain atrophy in multiple sclerosis (MS) are associated with disease progression. The motivation of this study was to propose and evaluate a new grouping scheme which is based on MS patients’ whole brain and thalamus volumes measured on MRI at a single time point. 2018.
This study compares clinical and MRI parameters between patients with clinically isolated syndrome and those converting to clinically definite multiple sclerosis within 2 years, to identify volumetric MRI predictors of this conversion and to assess effect of early relapses. 2012.
To assess whether single-time-point and longitudinal volumetric magnetic resonance (MR) imaging measures provide predictive prognostic information in patients with amnestic mild cognitive impairment (MCI). Radiology, June 2011.
Study to determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). 2011 October 12.
Authors Rahul Desikan et al from UCSD and UCSF describe a strategy to incorporate newly available imaging markers in the workup of memory problems, emphasizing that evidence of neurodegeneration can be an important piece of the puzzle to guide further management and testing, while helping to avoid overuse of more expensive biomarker tests. The paper highlights the way in which advanced neuroimaging tools such as Cortechs.ai’ NeuroQuant® volumetric MRI analysis system can provide information key to an improved understanding of the patient’s clinical status. (AJNR Am J Neuroradiology originally published online on June 13, 2013, 10.3174/ajnr.A3644)
Recently published in the journal Imaging in Medicine (June, 2012), Linda K. McEvoy and James B. Brewer argue that while incorporating biomarkers for assessing Alzheimer’s disease risk (including volumetric MRI done with NeuroQuant®) can help in patient prognosis, tests for amyloid, if used in isolation, have potential for harm, as amyloid tests are clinically useful only when evidence suggests progressive cognitive decline or neurodegeneration. (Imaging in Medicine, June 2012, Vol. 4, No. 3 , Pages 343-357).
Neuroimaging biomarkers are now routinely incorporated into AD clinical trials and are increasingly used in clinical practice. This paper broadly describes the development and use of these biomarkers as they relate to AD.
Scientists at the University of California, San Diego School of Medicine have shown that NeuroQuant®’s fully-automated volumetric MRI scanning is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer’s disease. The procedure can be readily used in clinics to measure brain atrophy, and may help physicians to predict decline in MCI patients.
NeuroQuant® Results Published in the American Journal of Neuroradiology.
A study to compare the accuracy of a volumetric fully automated computer assessment of hippocampal volume asymmetry versus neuroradiologists’ interpretations of the temporal lobes for mesial temporal sclerosis (MTS), which is important for patients with temporal lobe epilepsy. American Journal of Neuroradiology, 2015 April 23.
Quantitative MR imaging using NeuroQuant® can enhance standard visual analysis, providing a viable means for translating volumetric analysis into clinical practice and increasing the detection of hippocampal atrophy in temporal lobe epilepsy in both community and tertiary care settings. Radiology August 2012 264:542-550; Published online June 21, 2012.
Assessment of military veterans with PTSD and trauma-exposed control subjects, with sufficient power to perform a definitive assessment of the effect of PTSD on volumetric changes in the amygdala and hippocampus and of the contribution of illness duration, trauma load, and depressive symptoms. November 2012.
Prospective study of Traumatic Brain Injury (TBI) patients to investigate volume change in cortical grey matter (GM), hippocampus, lenticular nucleus, lobar white matter (WM), brainstem and ventricles.
A retrospective evaluation of ventricular shunt or EVD patients who underwent sequential head CT scans with an automated CT registration tool (CT CoPilot), assessing reader ability to discern change in ventricular volume between scans using standard axial CT images versus reformats and subtraction images generated by the registration tool. 2020.
Deep learning reconstruction allows 60% sequence scan-time reduction while maintaining high volumetric quantification
accuracy, consistent clinical classification, and what radiologists perceive as superior image quality compared with standard of care. This trial supports the reliability, efficiency, and utility of deep learning-based enhancement for quantitative imaging. Shorter scan times may heighten the use of volumetric quantitative MR imaging in routine clinical settings.
The automated volumetric assessment tool had moderate sensitivity (63.3%) and high specificity (100%) in differentiating patients with mild-to-moderate AD from control subjects. Visual inspection showed sensitivity of 63.3% and specificity of 92.0%. The diagnostic performance was not significantly different between the two methods (p =0.536–0.906). Intraobserver reliability for visual inspection was 0.858 and 0.902 for the two reviewers, and interobserver reliability was 0.692–0.780. (2016).
Magnetic resonance spectroscopy (MRS) has long showed promise for detection of regional chemical changes associated with neurodegeneration, infl ammation, or gliosis, and so it has been a technique of interest for detecting such changes in AD. It provides information about relative concentrations of key chemicals, such as N acetylaspartate, creatinine, and myoinositol, and there is strong evidence that the regional concentration of these chemicals varies with the neurodegeneration seen in AD. (2013).
This study examined whether measures of hippocampus, amygdala, and temporal horn volume predict clinical decline over the following 6-month period in patients with mild cognitive impairment (MCI). Fully automated volume measurements were performed in 269 MCI patients. Baseline volumes of the hippocampus, amygdala, and temporal horn were evaluated as predictors of change in Mini-mental State Examination and Clinical Dementia Rating Sum of Boxes over a 6-month interval. Fully automated measurements of baseline hippocampus and amygdala volumes correlated with baseline delayed recall scores. (2009).
Based on the evidence reviewed, the idea that brain volume changes and, to a lesser extent, spinal cord atrophy are helpful predictors of the evolution of MS before initiation of therapy is undisputed, so these measures could be valid treatment-decision tools. The evidence reviewed also supports the idea that brain volume measures have value in monitoring the effects of MS drugs as part of the no evidence of disease activity outcome measure or minimal evidence of disease activity outcome measure. However, several potential sources of substantial error remain, including, but not limited to, differential effects of drugs on brain volume measures, confounding physiological and technical factors and the performance and value of volumetric tools. To make implementation of volume measurements in clinical practice feasible, these potential sources of error need to be accounted for and appropriately managed, and further research is needed to ensure the accuracy and reliability of the measurements. (2020).
Thalamic atrophy and whole brain atrophy in multiple sclerosis (MS) are associated with disease progression. The motivation of this study was to propose and evaluate a new grouping scheme which is based on MS patients’ whole brain and thalamus volumes measured on MRI at a single time point. 2018.
This study compares clinical and MRI parameters between patients with clinically isolated syndrome and those converting to clinically definite multiple sclerosis within 2 years, to identify volumetric MRI predictors of this conversion and to assess effect of early relapses. 2012.
To assess whether single-time-point and longitudinal volumetric magnetic resonance (MR) imaging measures provide predictive prognostic information in patients with amnestic mild cognitive impairment (MCI). Radiology, June 2011.
Study to determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). 2011 October 12.
Authors Rahul Desikan et al from UCSD and UCSF describe a strategy to incorporate newly available imaging markers in the workup of memory problems, emphasizing that evidence of neurodegeneration can be an important piece of the puzzle to guide further management and testing, while helping to avoid overuse of more expensive biomarker tests. The paper highlights the way in which advanced neuroimaging tools such as Cortechs.ai’ NeuroQuant® volumetric MRI analysis system can provide information key to an improved understanding of the patient’s clinical status. (AJNR Am J Neuroradiology originally published online on June 13, 2013, 10.3174/ajnr.A3644)
Recently published in the journal Imaging in Medicine (June, 2012), Linda K. McEvoy and James B. Brewer argue that while incorporating biomarkers for assessing Alzheimer’s disease risk (including volumetric MRI done with NeuroQuant®) can help in patient prognosis, tests for amyloid, if used in isolation, have potential for harm, as amyloid tests are clinically useful only when evidence suggests progressive cognitive decline or neurodegeneration. (Imaging in Medicine, June 2012, Vol. 4, No. 3 , Pages 343-357).
Neuroimaging biomarkers are now routinely incorporated into AD clinical trials and are increasingly used in clinical practice. This paper broadly describes the development and use of these biomarkers as they relate to AD.
Scientists at the University of California, San Diego School of Medicine have shown that NeuroQuant®’s fully-automated volumetric MRI scanning is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer’s disease. The procedure can be readily used in clinics to measure brain atrophy, and may help physicians to predict decline in MCI patients.
NeuroQuant® Results Published in the American Journal of Neuroradiology.
A study to compare the accuracy of a volumetric fully automated computer assessment of hippocampal volume asymmetry versus neuroradiologists’ interpretations of the temporal lobes for mesial temporal sclerosis (MTS), which is important for patients with temporal lobe epilepsy. American Journal of Neuroradiology, 2015 April 23.
Quantitative MR imaging using NeuroQuant® can enhance standard visual analysis, providing a viable means for translating volumetric analysis into clinical practice and increasing the detection of hippocampal atrophy in temporal lobe epilepsy in both community and tertiary care settings. Radiology August 2012 264:542-550; Published online June 21, 2012.
Assessment of military veterans with PTSD and trauma-exposed control subjects, with sufficient power to perform a definitive assessment of the effect of PTSD on volumetric changes in the amygdala and hippocampus and of the contribution of illness duration, trauma load, and depressive symptoms. November 2012.
Prospective study of Traumatic Brain Injury (TBI) patients to investigate volume change in cortical grey matter (GM), hippocampus, lenticular nucleus, lobar white matter (WM), brainstem and ventricles.
A retrospective evaluation of ventricular shunt or EVD patients who underwent sequential head CT scans with an automated CT registration tool (CT CoPilot), assessing reader ability to discern change in ventricular volume between scans using standard axial CT images versus reformats and subtraction images generated by the registration tool. 2020.
© 2020 Cortechs.ai
